Alba Jiménez-Masip
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Alba Jiménez-Masip has a total of 81 co-authors. Here are the top co-authors by number of shared publications:
- Juan Manuel Pericas
Liver Unit, Vall d’Hebron University Hospital, Vall D’Hebron Institute for Research, Universitat Autònoma de Barcelona, 08035 Barcelona, Spain
6 shared publications - Sergio Muñoz-Martínez
Liver Unit, Digestive Diseases Division, Vall d’Hebron University Hospital, Barcelona, Spain
3 shared publications - Diego Rojo
Secció d’Hepatologia, Servei de Digestiu, Hospital del Mar, Barcelona, Spain
2 shared publications - Isabel Graupera
Liver Unit, Hospital Clínic of Barcelona, Barcelona, Spain; Fundació de Recerca Clínic Barcelona-Institut d'Investigacions Biomèdiques August Pi i Sunyer (FCRB-IDIBAPS), Barcelona, Spain; Centro de Investigación Biomédica en Red Enfermedades Hepáticas y Digestivas (CIBEREHD), Madrid, Spain
2 shared publications - Joan Genescà
Liver Unit, Vall d'Hebron Hospital Universitari, Vall d'Hebron Institut of Research (VHIR), Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain; Universitat Autònoma de Barcelona, Bellaterra, Spain; CIBEREHD, ISCIII, Madrid, Spain
2 shared publications - Laura Pagès
Liver Unit, Digestive Diseases Division, Vall d’Hebron University Hospital, Barcelona, Spain
2 shared publications
Latest Publications
- Open Access
- 19 June 2026
- Published by Wolters Kluwer Health in Hepatology Communications
- Vol. 10 (7)
Reply: Rethinking sustained recompensation in MASLD cirrhosis: The value of pharmacological maintenance
- 19 June 2026
- Published by Wolters Kluwer Health in Hepatology Communications
- Vol. 10 (7)
Open AccessReply: Rethinking sustained recompensation in MASLD cirrhosis: The value of pharmacological maintenance
- Open Access
- 11 March 2026
- Published by Wolters Kluwer Health in Hepatology Communications
- Vol. 10 (4)
The rate and predictors of recompensation in patients with decompensated cirrhosis due to metabolic dysfunction–associated liver disease (MASLD)
Background: Whether patients with metabolic dysfunction–associated steatotic liver disease (MASLD) cirrhosis can achieve recompensation is still a subject of debate. This study aimed to evaluate the incidence and factors associated with recompensation in patients with decompensated MASLD cirrhosis. Methods: Cohort study across 4 university hospitals in Barcelona (Spain), enrolling individuals with MASLD cirrhosis at their initial decompensating event. Liver recompensation (Baveno VII) was defined as the absence of clinical decompensation after discontinuation of specific treatment, along with sustained improvement in liver function. Competing-risk regression models were used to identify predictors of recompensation. Results: Among 124 patients [mean age: 69 years (IQR 62–73), 53% males], 59% had obesity, 74% type 2 diabetes, 66% arterial hypertension, and 47% dyslipidemia. Most patients were Child–Pugh B (61%) with a median MELD-Na score of 11 (IQR 10–16). After a median follow-up of 2.1 years (IQR 0.97–4.53), the 2-year cumulative incidence of recompensation was 24%. Factors associated with recompensation included MELD-Na (aSHR 0.891 [95% CI 0.833–0.953]; p =0.001), albumin (aSHR 1.894 [95% CI 1.008–3.297]; p =0.024, ascites (aSHR 0.475, [95% CI 0.268–0.841]; p =0.011), and multiple decompensation (aSHR 0.151 [94% CI 0.033–0.698]; p =0.015) as a first decompensation event. Although a substantial proportion of patients initially achieved recompensation, this was frequently transient, and its apparent survival benefit did not persist after adjustment for liver function and accounting for time-dependence. Conclusions: Liver recompensation in MASLD cirrhosis occurs in 24% of patients within 2 years after first decompensation and is mainly dependent on basal liver function. However, frequent further decompensation limits its prognostic impact on survival.
- 11 March 2026
- Published by Wolters Kluwer Health in Hepatology Communications
- Vol. 10 (4)
Open AccessThe rate and predictors of recompensation in patients with decompensated cirrhosis due to metabolic dysfunction–associated liver disease (MASLD)
Background: Whether patients with metabolic dysfunction–associated steatotic liver disease (MASLD) cirrhosis can achieve recompensation is still a subject of debate. This study aimed to evaluate the incidence and factors associated with recompensation in patients with decompensated MASLD cirrhosis. Methods: Cohort study across 4 university hospitals in Barcelona (Spain), enrolling individuals with MASLD cirrhosis at their initial decompensating event. Liver recompensation (Baveno VII) was defined as the absence of clinical decompensation after discontinuation of specific treatment, along with sustained improvement in liver function. Competing-risk regression models were used to identify predictors of recompensation. Results: Among 124 patients [mean age: 69 years (IQR 62–73), 53% males], 59% had obesity, 74% type 2 diabetes, 66% arterial hypertension, and 47% dyslipidemia. Most patients were Child–Pugh B (61%) with a median MELD-Na score of 11 (IQR 10–16). After a median follow-up of 2.1 years (IQR 0.97–4.53), the 2-year cumulative incidence of recompensation was 24%. Factors associated with recompensation included MELD-Na (aSHR 0.891 [95% CI 0.833–0.953]; p =0.001), albumin (aSHR 1.894 [95% CI 1.008–3.297]; p =0.024, ascites (aSHR 0.475, [95% CI 0.268–0.841]; p =0.011), and multiple decompensation (aSHR 0.151 [94% CI 0.033–0.698]; p =0.015) as a first decompensation event. Although a substantial proportion of patients initially achieved recompensation, this was frequently transient, and its apparent survival benefit did not persist after adjustment for liver function and accounting for time-dependence. Conclusions: Liver recompensation in MASLD cirrhosis occurs in 24% of patients within 2 years after first decompensation and is mainly dependent on basal liver function. However, frequent further decompensation limits its prognostic impact on survival.
- Open Access
- 29 October 2025
- Published by Esmon Publicidad, SA in Revista Espanola de Sanidad Penitenciaria
- Vol. 27 (3) , 122-134
Metabolic dysfunction-associated steatotic liver disease in prison populations: a review of its impact and current and future challenges
Objectives: Review the epidemiology of metabolic dysfunction-associated steatotic liver disease (MASLD), and the main diagnostic and therapeutic challenges, with a specific focus on its management in the prison population. Material and method: MASLD is the most prevalent form of chronic liver disease worldwide and represents an increasing challenge for public health and healthcare systems. Prison inmates are particularly vulnerable to this condition due to a combination of individual and social factors and to characteristics within the correctional system itself. These vulnerabilities have contributed to an epidemiological transition, whereby metabolic comorbidities have replaced transmittable diseases as the main cause of morbimortality, Conclusions: The growing burden of metabolic disease in correctional settings underscores the urgent need for effective screening and referral strategies for early MASLD detection. However, current protocols remain poorly defined, and there is limited evidence regarding their cost-effectiveness in this specific context. These gaps highlight the pressing need for further research and the development of public health policies tailored to the unique characteristics of this high-risk population.
- 29 October 2025
- Published by Esmon Publicidad, SA in Revista Espanola de Sanidad Penitenciaria
- Vol. 27 (3) , 122-134
Open AccessMetabolic dysfunction-associated steatotic liver disease in prison populations: a review of its impact and current and future challenges
Objectives: Review the epidemiology of metabolic dysfunction-associated steatotic liver disease (MASLD), and the main diagnostic and therapeutic challenges, with a specific focus on its management in the prison population. Material and method: MASLD is the most prevalent form of chronic liver disease worldwide and represents an increasing challenge for public health and healthcare systems. Prison inmates are particularly vulnerable to this condition due to a combination of individual and social factors and to characteristics within the correctional system itself. These vulnerabilities have contributed to an epidemiological transition, whereby metabolic comorbidities have replaced transmittable diseases as the main cause of morbimortality, Conclusions: The growing burden of metabolic disease in correctional settings underscores the urgent need for effective screening and referral strategies for early MASLD detection. However, current protocols remain poorly defined, and there is limited evidence regarding their cost-effectiveness in this specific context. These gaps highlight the pressing need for further research and the development of public health policies tailored to the unique characteristics of this high-risk population.
- Open Access
- 1 October 2025
- Published by AME Publishing Company in HepatoBiliary Surgery and Nutrition
- Vol. 14 (5) , 824-828
Opportunistic case-finding of liver fibrosis in metabolic dysfunction-associated steatotic liver disease (MASLD) by leveraging integrated care pathways of type 2 diabetes
Opportunistic case-finding of liver fibrosis in metabolic dysfunction-associated steatotic liver disease (MASLD) by leveraging integrated care pathways of type 2 diabetes
- 1 October 2025
- Published by AME Publishing Company in HepatoBiliary Surgery and Nutrition
- Vol. 14 (5) , 824-828
Open AccessOpportunistic case-finding of liver fibrosis in metabolic dysfunction-associated steatotic liver disease (MASLD) by leveraging integrated care pathways of type 2 diabetes
Opportunistic case-finding of liver fibrosis in metabolic dysfunction-associated steatotic liver disease (MASLD) by leveraging integrated care pathways of type 2 diabetes
- 30 May 2025
- Published by Springer Nature in Current Hepatology Reports
- Vol. 24 (1) , 1-14
GLP-1 and Glucagon Receptor Dual Agonists in the Management of Metabolic Dysfunction-associated Steatotic Disease (MASLD)
- 30 May 2025
- Published by Springer Nature in Current Hepatology Reports
- Vol. 24 (1) , 1-14
GLP-1 and Glucagon Receptor Dual Agonists in the Management of Metabolic Dysfunction-associated Steatotic Disease (MASLD)
- Open Access
- 24 November 2023
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 12 (23) , 7276
Prevalence and Risk Factors of MASLD and Liver Fibrosis amongst the Penitentiary Population in Catalonia: The PRISONAFLD Study
Background and Aims: The prevalence of chronic non-communicable diseases, particularly metabolic syndrome (MetS), has increased among the prison population. Nevertheless, we have limited data on metabolic dysfunction-associated steatotic liver disease (MASLD), the hepatic manifestation of this syndrome. We aimed to investigate the prevalence and risk factors of MASLD and MASLD-associated liver fibrosis in the penitentiary population in Catalonia, Spain. Method: A cross-sectional observational study involving eight penitentiary centers. Participants had at least one metabolic disorder and were at a closed-regimen penitentiary. Individuals with concomitant liver diseases and/or alcohol risk consumption were excluded. Significant fibrosis and MASLD were defined as liver stiffness ≥8 kPa and a controlled attenuation parameter ≥275 dB/m by vibration-controlled transient elastography (VCTE), respectively. After exclusions, metabolic inmates with VCTE were analyzed. Logistic regression analysis was performed to identify predictors of MASLD and MASLD-associated significant fibrosis. Results: Out of the 4338 inmates studied, 1290 (29.7%) had metabolic disorders, and 646 (14.9%) underwent VCTE. The mean age was 48.0 years (SD 12.1), and 89.5% were male. MASLD prevalence was 33.9%. Significant fibrosis and MASLD-associated significant fibrosis were found in 16.4% and 9.4% of inmates, respectively. In the multivariate analysis, T2D, waist circumference, MetS, and higher ALT values were identified as independent risk factors for MASLD and MASLD-associated significant fibrosis amongst the prison population. Conclusions: Metabolic disorders including MASLD are highly prevalent among inmates. The prevalence of significant fibrosis seems notably higher than that of the general population, underscoring the need for targeted screening programs and therapeutic interventions in the incarcerated population.
- 24 November 2023
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 12 (23) , 7276
Open AccessPrevalence and Risk Factors of MASLD and Liver Fibrosis amongst the Penitentiary Population in Catalonia: The PRISONAFLD Study
Background and Aims: The prevalence of chronic non-communicable diseases, particularly metabolic syndrome (MetS), has increased among the prison population. Nevertheless, we have limited data on metabolic dysfunction-associated steatotic liver disease (MASLD), the hepatic manifestation of this syndrome. We aimed to investigate the prevalence and risk factors of MASLD and MASLD-associated liver fibrosis in the penitentiary population in Catalonia, Spain. Method: A cross-sectional observational study involving eight penitentiary centers. Participants had at least one metabolic disorder and were at a closed-regimen penitentiary. Individuals with concomitant liver diseases and/or alcohol risk consumption were excluded. Significant fibrosis and MASLD were defined as liver stiffness ≥8 kPa and a controlled attenuation parameter ≥275 dB/m by vibration-controlled transient elastography (VCTE), respectively. After exclusions, metabolic inmates with VCTE were analyzed. Logistic regression analysis was performed to identify predictors of MASLD and MASLD-associated significant fibrosis. Results: Out of the 4338 inmates studied, 1290 (29.7%) had metabolic disorders, and 646 (14.9%) underwent VCTE. The mean age was 48.0 years (SD 12.1), and 89.5% were male. MASLD prevalence was 33.9%. Significant fibrosis and MASLD-associated significant fibrosis were found in 16.4% and 9.4% of inmates, respectively. In the multivariate analysis, T2D, waist circumference, MetS, and higher ALT values were identified as independent risk factors for MASLD and MASLD-associated significant fibrosis amongst the prison population. Conclusions: Metabolic disorders including MASLD are highly prevalent among inmates. The prevalence of significant fibrosis seems notably higher than that of the general population, underscoring the need for targeted screening programs and therapeutic interventions in the incarcerated population.
- 9 March 2022
- Published by Elsevier in Gastroenterología y Hepatología
- Vol. 46 (1) , 10-16
Underlying etiology associated with the diagnosis of absent contractility on high resolution esophageal manometry
- 9 March 2022
- Published by Elsevier in Gastroenterología y Hepatología
- Vol. 46 (1) , 10-16
Underlying etiology associated with the diagnosis of absent contractility on high resolution esophageal manometry